After a deadly clinical trial, will immune therapies for cancer be a bust?
By Damian Garde,
STAT
| 07. 08. 2016
Immune therapies have been hailed as the future of cancer treatments, with new drugs racking up excellent clinical results by turning the body’s natural defenses on tumors.
But Thursday’s news that three patients died in a trial of one such treatment has surprised oncologists and biotech investors, casting doubts on what looked like a blockbuster new approach to fighting cancer.
Here’s a rundown on the fatal trial and what it means for the rest of the field.
Continue reading on STAT
Image via Flickr/NIH Image Gallery
Related Articles
By Charles Schmidt, Undark | 09.25.2026
In 2010, scientists at the University of Tokyo and other institutions reported a startling achievement: They had successfully grown a pancreas made almost entirely of rat cells within the bodies of mice. The research was directed by Hiromitsu Nakauchi, a...
By Rob Stein, NPR [cites CGS' Katie Hasson] | 09.29.2026
Cathy Tie slips on a white lab coat bearing her name and the logo of her startup: Origin Genomics. "Welcome!" she says as she leads an NPR reporter, photographer and videographer on an exclusive tour of Origin's labs located...
By Erik Adams, Sundance | 09.08.2026
The scariest movie playing at the 2026 Sundance Film Festival isn’t about cursed audio recordings or a killer demon disguised as your true love; rather it’s a 110-minute essay film about how a handful of guys obsessed with numbers and...
Artificial Intelligence (AI) has been a major focus of news recently, as it should have been, under the appropriately ridiculous name of Hugging Face, “a leading collaboration platform and community hub for machine learning, artificial intelligence, and data science.” In July, Hugging Face was hacked. The platform itself responded:
Earlier this week, we detected and responded to an intrusion into part of our production infrastructure. This one was different from anything we had handled before in one important way...
